Novus Health Services, Inc.

novushs.com

Our goal is to focus on the root of why hospice care began in this country-quality of life. Specifically we provide personalized care to ensure our patients get the most out of their days, weeks, months or years – spending worthwhile time doing what makes them happy – however they want to do it. Most importantly we ensure our patients are pain free and as comfortable as possible throughout their life. We do not believe it is our place to dictate how a patient chooses to live. Patients have the right to remain active and alert and present despite any illness they may have.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Pharmacy Market

ASTELLAS ANNOUNCES TOPLINE RESULTS FROM PHASE 3 LONG-TERM SAFETY STUDY OF FEZOLINETANT IN MAINLAND CHINA

Astellas Pharma Inc. | September 05, 2022

news image

Astellas Pharma Inc. announced topline results from the Phase 3 MOONLIGHT 3™ clinical trial in women in mainland China evaluating the long-term safety and tolerability of fezolinetant, an investigational oral, nonhormonal compound being studied for the treatment of moderate to severe vasomotor symptoms associated with menopause. VMS, characterized by hot flashes and/or night sweats, are common symptoms of menopause. MOONLIGHT 3 is a 52-week single-arm Phase 3 clinical trial ...

Read More

Business Insights, PHARMA TECH

NORTHSTAR AND INHIBRX JOIN HANDS TO DEVELOP RADIOPHARMACEUTICAL CANDIDATES

Northstar and Inhibrx | January 09, 2023

news image

NorthStar Medical Radioisotopes, LLC, announced a collaboration with Inhibrx, Inc., to develop and produce new radiopharmaceuticals for cancer treatment. Inhibrx will develop a new generation of targeted alpha treatments utilizing its improved single-domain antibodies (sdAbs). With a long history of sdAb innovation, it has created a library of sdAbs targeting tumor-associated antigens. Its high binding affinity and specificity for tumor cells or antigen-expressing cells within the...

Read More

Pharma Tech

HOLOGIC LAUNCHES PANTHER TRAX FOR HIGH VOLUME MOLECULAR TESTING

Hologic | December 24, 2021

news image

Hologicannounced that it has completed regulatory filings needed to make Panther Trax® available in a number of countries and regions. Launch of Panther Trax represents the latest addition to the Panther® Scalable Solutions portfolio of products, offering the ultimate in lab automation by physically linking multiple Panther instruments together into a single, powerful workcell that allows labs to increase testing volumes without increasing staff. Panther Trax is now listed...

Read More

Pharmacy Market

ALCAMI ADDS ADDITIONAL FORMULATION DEVELOPMENT CAPABILITIES

Alcami Corporation | March 02, 2022

news image

Alcami, a U.S.-based pharmaceutical contract development and manufacturing organization announced the addition of a 3,800 ft² Non-GMP Formulation Development Laboratory (FDL). The dedicated Non-GMP formulation development space, which is co-located within the same facility as Alcami's parenteral manufacturing operation that offers four isolator filling lines for liquid and lyophilized products, is ready to support customers with Preclinical and Clinical development programs. Read More

news image

Pharmacy Market

ASTELLAS ANNOUNCES TOPLINE RESULTS FROM PHASE 3 LONG-TERM SAFETY STUDY OF FEZOLINETANT IN MAINLAND CHINA

Astellas Pharma Inc. | September 05, 2022

Astellas Pharma Inc. announced topline results from the Phase 3 MOONLIGHT 3™ clinical trial in women in mainland China evaluating the long-term safety and tolerability of fezolinetant, an investigational oral, nonhormonal compound being studied for the treatment of moderate to severe vasomotor symptoms associated with menopause. VMS, characterized by hot flashes and/or night sweats, are common symptoms of menopause. MOONLIGHT 3 is a 52-week single-arm Phase 3 clinical trial ...

Read More
news image

Business Insights, PHARMA TECH

NORTHSTAR AND INHIBRX JOIN HANDS TO DEVELOP RADIOPHARMACEUTICAL CANDIDATES

Northstar and Inhibrx | January 09, 2023

NorthStar Medical Radioisotopes, LLC, announced a collaboration with Inhibrx, Inc., to develop and produce new radiopharmaceuticals for cancer treatment. Inhibrx will develop a new generation of targeted alpha treatments utilizing its improved single-domain antibodies (sdAbs). With a long history of sdAb innovation, it has created a library of sdAbs targeting tumor-associated antigens. Its high binding affinity and specificity for tumor cells or antigen-expressing cells within the...

Read More
news image

Pharma Tech

HOLOGIC LAUNCHES PANTHER TRAX FOR HIGH VOLUME MOLECULAR TESTING

Hologic | December 24, 2021

Hologicannounced that it has completed regulatory filings needed to make Panther Trax® available in a number of countries and regions. Launch of Panther Trax represents the latest addition to the Panther® Scalable Solutions portfolio of products, offering the ultimate in lab automation by physically linking multiple Panther instruments together into a single, powerful workcell that allows labs to increase testing volumes without increasing staff. Panther Trax is now listed...

Read More
news image

Pharmacy Market

ALCAMI ADDS ADDITIONAL FORMULATION DEVELOPMENT CAPABILITIES

Alcami Corporation | March 02, 2022

Alcami, a U.S.-based pharmaceutical contract development and manufacturing organization announced the addition of a 3,800 ft² Non-GMP Formulation Development Laboratory (FDL). The dedicated Non-GMP formulation development space, which is co-located within the same facility as Alcami's parenteral manufacturing operation that offers four isolator filling lines for liquid and lyophilized products, is ready to support customers with Preclinical and Clinical development programs. Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us